Rotigaptide

Rotigaptide (ZP123) is a novel and specific modulator of connexin 43 (Cx43) . Rotigaptide prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress. Rotigaptide is a potent antiarrhythmic peptide (AAP) with improved stability and has the potential for the investigation of cardiac arrhythmias-specifically atrial fibrillation[1][2].

Product Specifications

CAS Number

[355151-12-1]

Product Name Alternative

ZP123

UNSPSC

12352005

Target

Connexin; Gap Junction Protein

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/rotigaptide.html

Purity

99.81

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N)CNC([C@@H](C)NC(CNC([C@@H]1N(C([C@@H]2N(C([C@@H](CC3=CC=C(O)C=C3)NC(C)=O)=O)CCC2)=O)C[C@@H](O)C1)=O)=O)=O

Molecular Formula

C28H39N7O9

Molecular Weight

617.65

References & Citations

[1]Seyed Mojtaba Ghiasi, et al. The connexin 43 regulator Rotigaptide reduces cytokine-induced cell death in human islets|[2]Stahlhut M, et al. The antiarrhythmic peptide rotigaptide (ZP123) increases connexin 43 protein expression in neonatal rat ventricular cardiomyocytes.Cell Commun Adhes. 2006 Jan-Apr;13 (1-2) :21-7.|[3]Kjølbye AL, et al. Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias.Basic Clin Pharmacol Toxicol. 2007 Oct;101 (4) :215-30.